Genomics Shared Resource

项目概要-基因组学共享资源 基因组学共享资源（GSR）提供最先进的基础设施和支持， 癌症中心（CC）研究人员的功能基因组学研究。训练有素的工作人员和他们的努力， 在不降低服务的情况下保持成本，为CC成员提供最新的基因组 以最低的成本获得技术。海矿资源公司一直与快速发展的技术保持同步， 该中心在外地设立了办事处，并扩大了其能力，以应对气候变化的需要。GSR支持大量的 功能基因组学研究的应用，包括现场下一代（NG）测序， 通过增加Illumina NextSeq 500系统来实现这一融资周期。其他新服务于 对用户会议、个人协商和CC领导层的投入作出回应。新服务 包括购买Wafergen ICell 8系统的单细胞测序能力， 的基于微阵列的基因表达分析与NG 3'末端测序。免放大NanoString平台 使用定制的或市售的板进行靶基因表达， 建立了NanoString RNA-Protein应用。新鲜或福尔马林固定的基因和microRNA测定 石蜡包埋（FFPE）的人体组织是常规的。海矿资源公司制定并改进了协议， 用于对具有有限RNA的少量细胞进行研究以评估特定细胞类型的产量。最后， GSR实施了一种基于qPCR的牛棒状杆菌检测试验，使CC成员能够 在动物粪便和组织样本中识别这种病原体，加强与动物 共享资源，并建立了用于细胞系验证的小鼠和人类微卫星测定。期间 在CCSG的上一个预算周期，GSR搬进了位于西翼的一个新装修的1,733个NSF实验室 研究所的所有癌症中心的研究人员都可以轻松访问。基于协作数据分析 管道已经到位与生物信息学共享资源，GSR成功地建立了一个 集成的研究平台，包括分子筛选共享资源，以促进 从shRNA筛选到NG测序和生物信息学分析的前导序列的鉴定， 多学科的科学连续体。GSR继续提供关键的常规服务，包括毛细管 测序、启动子甲基化研究和定量实时PCR。利用快速增长的 测序成本的可负担性，以及提供的高质量，可靠，个性化的服务， 在下一个CCSG预算周期，GSR将继续成为CC调查人员的关键资产。的GSR 计划加大在功能基因组学方面的努力，以应对表观遗传学领域的师资扩张， 癌症疫苗和免疫学。GSR对特定疾病地点的项目也至关重要，特别是在 卵巢癌、肺癌和黑色素瘤，结合联合收割机多学科方法， 评估大量患者样本。

PROJECT SUMMARY – GENOMICS SHARED RESOURCE The Genomics Shared Resource (GSR) provides state-of-the-art infrastructure and support for integrated functional genomics studies of Cancer Center (CC) investigators. The highly trained staff and their efforts to maintain costs without diminishing service, provides CC members with access to the latest genomic technologies at a minimum cost. The GSR has kept pace with rapidly moving technological developments in the field and expanded its capabilities in response to CC needs. The GSR supports a large portfolio of applications for functional genomics research, including on-site Next-Generation (NG) sequencing, provided in this funding cycle by the addition of an Illumina NextSeq500 system. Other new services were added in response to input from user meetings, individual consultations and input from CC leadership. The new services included single-cell sequencing capabilities with the purchase of a Wafergen ICell8 system, and replacement of microarray-based gene expression analysis with NG 3’ end-seq. An amplification-free NanoString platform was implemented to carry out targeted gene expression using custom or commercially available panels and a NanoString RNA-Protein application was established. Gene and microRNA assays on fresh or formalin-fixed paraffin-embedded (FFPE) human tissues are routine. The GSR has established and improved protocols and yields for studies on small numbers of cells with limited RNA for the assessment of specific cell types. Lastly, the GSR implemented a qPCR-based Corynebacterium bovis detection assay that allows CC members to identify this pathogen in animal fecal and tissue samples, strengthening collaborative efforts with the Animal Shared Resource, and established mouse and human microsatellite assays for cell line verification. During the last CCSG budget cycle, the GSR moved into a newly renovated 1,733 NSF laboratory space in the west wing of the Institute with ease of access to all Cancer Center investigators. Building on a collaborative data analysis pipeline already in place with the Bioinformatics Shared Resource, the GSR successfully established an integrated research platform that includes the Molecular Screening Shared Resource to facilitate the identification of leads from shRNA screens to NG sequencing and Bioinformatics analysis in a productive, multidisciplinary scientific continuum. The GSR continues to provide critical routine services including capillary sequencing, promoter methylation studies and quantitative real-time PCR. Leveraging the rapidly increasing affordability of sequencing costs, together with the high-quality, reliable, personalized services provided, the GSR will continue to be a pivotal asset for CC investigators during the next CCSG budget cycle. The GSR plans to grow efforts in functional genomics in response to faculty expansion in the areas of epigenetics, cancer vaccines and immunology. The GSR is also critical to disease site-specific projects, particularly in ovarian cancer, lung cancer and melanoma that combine multidisciplinary approaches and require the assessment of large numbers of patient samples.